IMW 2019 | AML: Vaccination, hypomethylation and CAR-T

David Avigan

David Avigan, MD, Harvard Medical School, Boston, MA, discusses the efficacy of using hypomethylating agents to increase the potency of dendritic cell hybridoma acute myeloid leukemia (AML) vaccines. Dr Avigan also discusses how the combination of the aforementioned vaccine with CAR T-cell therapy may offer a potentially powerful therapy for patients. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video